Assessment of total and dust mite–specific IgE and asthma and allergic rhinitis in recipients and their atopic donors before and after bone marrow transplantation
. | D farinae RAST, class 0-5 Recipient . | . | . | . | IgE level, U/mL Recipient . | . | Donor . | . | Asthma and allergic rhinitis†Recipient . | . | . | . | . | . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | 1 y after BMT . | More than 14 y after BMT . | . | More than 14 y after BMT . | . | . | Before BMT . | . | 1 y after BMT . | . | More than 14 y after BMT . | . | ||||||||||
| Patient no.* . | Donor . | Before BMT . | . | . | Before BMT . | . | AS severity . | AR severity . | AS severity . | AR severity . | AS severity . | AR severity . | AS severity . | AR severity . | ||||||||||
| 1 | 4 | 0 | 3 | 1 | 17 | 731 | 1 + | 2 + | 0 | 0 | 0 | 2 + | 1 + | 2 + | ||||||||||
| 2 | 2 | 0 | 2 | 4 | < 5 | 839 | 1 + | 2 + | 0 | 2 + | 0 | 3 + | 0 | 2 + | ||||||||||
| 3 | 0 | 0 | 0 | 0 | 13 | 36 | 0 | 1 + | 0 | 0 | 2 + | 2 + | 3 + | 2 + | ||||||||||
| 6 | 0 | 0 | 0 | 0 | 7 | 271 | 2 + | 2 + | 2 + | 2 + | 3 + | 2 + | 2 + | 2 + | ||||||||||
| 11 | 3 | 0 | 0 | 0 | 7 | 8 | 0 | 1 + | 0 | 0 | 0 | 1 + | 2 + | 2 + | ||||||||||
. | D farinae RAST, class 0-5 Recipient . | . | . | . | IgE level, U/mL Recipient . | . | Donor . | . | Asthma and allergic rhinitis†Recipient . | . | . | . | . | . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | 1 y after BMT . | More than 14 y after BMT . | . | More than 14 y after BMT . | . | . | Before BMT . | . | 1 y after BMT . | . | More than 14 y after BMT . | . | ||||||||||
| Patient no.* . | Donor . | Before BMT . | . | . | Before BMT . | . | AS severity . | AR severity . | AS severity . | AR severity . | AS severity . | AR severity . | AS severity . | AR severity . | ||||||||||
| 1 | 4 | 0 | 3 | 1 | 17 | 731 | 1 + | 2 + | 0 | 0 | 0 | 2 + | 1 + | 2 + | ||||||||||
| 2 | 2 | 0 | 2 | 4 | < 5 | 839 | 1 + | 2 + | 0 | 2 + | 0 | 3 + | 0 | 2 + | ||||||||||
| 3 | 0 | 0 | 0 | 0 | 13 | 36 | 0 | 1 + | 0 | 0 | 2 + | 2 + | 3 + | 2 + | ||||||||||
| 6 | 0 | 0 | 0 | 0 | 7 | 271 | 2 + | 2 + | 2 + | 2 + | 3 + | 2 + | 2 + | 2 + | ||||||||||
| 11 | 3 | 0 | 0 | 0 | 7 | 8 | 0 | 1 + | 0 | 0 | 0 | 1 + | 2 + | 2 + | ||||||||||
Patient number is based on designation in the original cohort.1
Severities of asthma (AS) and allergic rhinitis (AR) were graded according to the following scale: 0, no symptoms; 1 +, mild symptoms not treated with medications; 2 +, moderate symptoms treated intermittently without corticosteroids; and 3 +, severe symptoms requiring periods of corticosteroid therapy or daily treatment with noncorticosteroid medications.